TQB2103

TQB2103 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a protein highly expressed on certain tumor cells, particularly in gastric and pancreatic cancers[1][2][5]. Developed by Sino Biopharm and its subsidiary Chia Tai Tianqing Pharmaceutical Group, TQB2103 consists of a monoclonal antibody specific for CLDN18.2 linked to a cytotoxic payload that acts as a DNA topoisomerase I inhibitor[1][4][5]. Upon binding to CLDN18.2-expressing tumor cells, the ADC is internalized and the cytotoxic agent is released inside lysosomes via enzymatic cleavage of the linker, causing DNA damage and cell death[1][2]. The drug also exhibits a bystander effect that can kill adjacent tumor cells lacking CLDN18.2 expression[2]. Preclinical studies have shown significant inhibition of growth in CLDN18.2-positive human gastric and pancreatic cancer models with acceptable toxicity profiles in animal studies[2].

Other names

anti-CLDN18.2 antibody-drug conjugate TQB2103anti-CLDN-18.2 antibody-drug conjugate TQB2103anti-CLDN 18.2 antibody-drug conjugate TQB2103Claudin18.2 ADCClaudin-18.2 ADCClaudin 18.2 ADC